ABSTRACT OF THE WEEK

Journal of feline medicine and surgery
Volume 13 | Issue 10 (October 2011)

Safety and palatability of polyethylene glycol 3350 as an oral laxative in cats.

J Feline Med Surg. October 2011;13(10):694-7.

Fiona M Tam¹, Anthony P Carr, Sherry L Myers

¹ Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. fiona.tam@usask.ca

Abstract

Recurrent constipation is a common problem in cats. Laxatives often are the cornerstone for management of recurrent constipation; however, there is a paucity of published research on laxative use in cats. This study investigated the safety and palatability of polyethylene glycol (PEG3350) in normal cats. All cats consumed the PEG3350 laxative for 4 weeks without changes in weight or food intake. In all cats soft stools were achieved. Effective doses varied widely in experimental cats, so individualized dosing is important. Mild, non-clinical hyperkalemia was noted although the cause is unknown.

Companion Notes

Report on the safety and palatability of polyethylene glycol 3350 as an oral laxative in normal cats

Study design

- introduction on the treatment of constipation in cats

- laxatives commonly used as part of management

- polyethylene glycol (PEG3350) is a bulking and softening agent

- large molecular weight, water-soluble polymer

- in human medicine widely used as an osmotic laxative

- not metabolized by intestinal bacterial

- minimally absorbed

- each molecule hydrogen bonds with 100 molecules of water

- this results in high osmotic pressures in bowel lumen

- this acts against the absorption of water out of the lumen

- in multiple meta-analyses

- PEG3350 a more effective laxative than lactulose

- as well as many other oral laxatives

- adverse events are self-limiting and include the following:

- distended abdomen with pain

- nausea

- excessive diarrhea

- clinical hyponatremia not documented with daily low-dose use

- lactulose is a commonly used osmotic laxative

- in human medicine

- moderate evidence of efficacy and safety for chronic constipation

- in veterinary medicine: no evidence to support use

- soluble and insoluble dietary fibers

- in human medicine

- weak evidence of efficacy and safety for chronic constipation

- in feline medicine: no evidence to support use

- study population: 6 healthy cats from 1-4 years of age in a closed colony

- there was no history of diarrhea or constipation in the colony

- procedure:

- pilot trial on 2 of the cats to determine an effective initial dose

- treatment trial for 4 weeks

- PEG3350 with electrolytes (Colyte oral solution; Schwarz Pharma)

- 1.9 g per meal with the powder mixed with food

- cats were fed twice daily

(Iams, ProActive Adult formula, canned and dry)

- standard weight of canned and dry food offered each meal

- unconsumed amount weighed

- dosage titrated in each cat to achieve soft, formed stool (grade II-III)

- initial dose doubled if no effect seen within 48 hours

- assessment methods:

- fecal scores assessed daily; standardized fecal grading scale used

- grade I: over 66% of feces are liquid

- grade II: intermediate consistency between soft and liquid

- equal amounts of feces are soft and liquid

- grade III: over 66% of feces is soft

- firm enough to form a pile (no cylindrical appearance)

- grade IV: intermediate between firm and soft

- equal amounts of feces are firm and soft

- grade V: over 66% of feces in a defecation are firm

- cylindrical shape with little flattening

- CBC and chemistry before and 2 and 4 weeks after starting PEG3350

- palatability assessed by food intake and weight

- treatment stopped after 4 weeks

- cats monitored until stool consistency was normal for 2 defecations

Results

- grade I-III stool consistency achieved in all cats

- target consistency achieved in a median of 21.5 days

- median daily dose of powder to achieve target fecal grade: 3.0 ± 1.1 g

- median daily doses of the 6 cats to achieve target fecal grade

- 0.8, 1.5, 3.0, 3.0, 3.8 and 3.8 g

- dosage may be highly variable between cats

- diarrhea occasionally noted during treatment, 4 cats

- PEG3350 dosage decreased

- median time to return to normal consistency after stopping: 5.5 ± 3.4 days

- adverse event: no significant side effects noted in any cat

- sporadic vomiting, 1 cat during the treatment

- mild hyperkalemia, 3 cats at 5.6-6.0 mmol/l with reference at 3.9-5.5 mmol/l

- not associated with clinical signs in any of the cats

- food intake and body weight not significantly changed by PEG3350

“Our study demonstrated that PEG3350 with electrolytes is a safe and palatable oral laxative in healthy cats when used for 4 weeks. Potential side-effects include hyperkalemia; however, the changes we noted were not clinically or statistically significant.”

Article Tools:

Medline

Full Text on the Web

Email to me

Archives Highlights:

Discrepancies between Genetic and Visual Coat Color Assignment in Sarcidano Horse.
From the genetic analysis, Chestnuts (n = 58) resulted the most common Sarcidano Horse (n = 58), followed by a quite large number of Blacks (n = 28) and a very small number of Bays (n = 4), whereas phenotypic distribution resulted in 38 Chestnuts, 40 Bays, only 2 Blacks, and 10 Grays (without the possibility of recognizing the true color they carried). Chestnut resulted a very representative coat color, while many horses that visually identified as Bays were genetically Blacks. The error rate (calculated as the number of incorrectly classified color phenotypes in the total number of genetically assigned coat colors) was 53.4%, including the gray horses.

Dimethyl sulfoxide favors the emetic efficacy of lycorine in beagle dogs - a novel strategy for the treatment of poisoning.
By emesis response analysis four dimethyl sulfoxide (DMSO)-based active pharmaceutical ingredient (API) formulations were favored. Two of them (lycorine hydrochloride, 15 mg/mL in 70% DMSO, 10% ethanol, and 20% water; and lycorine hydrochloride, 15 mg/mL in 50% DMSO, 50% water) qualified for further drug development. Both formulations ensure a safe pharmacologically induced emesis within about 30 min after injection, suitable for use as an in time decontaminant in acute poisoning of dogs. DMSO-based formulations were well tolerated and offer a novel promising strategy for treatment of poisoning.

Risk factors for unilateral cranial cruciate ligament rupture diagnosis and for clinical management in dogs under primary veterinary care in the UK.
After accounting for confounding factors, dogs aged 6 to less than 9 years, male neutered and female neutered dogs, insured dogs, and Rottweiler, Bichon Frise, and West Highland White terrier breeds, in particular, had increased odds of unilateral CCL rupture diagnosis. Insured dogs and dogs = 20 kg had increased odds of surgical management, while dogs = 9 years and dogs with one non-orthopaedic comorbidity at diagnosis with CCL rupture had reduced odds. These findings inform identification of at-risk dogs.

Understanding the Role of Therapy Dogs in Human Health Promotion.
Therapy dog programmes are delivered across a variety of settings including hospitals, aged care facilities and mental health services, highlighting the important role they play in human health outcomes. Research has shown that that there are biomarkers for stress in humans and other animals engaged in human-animal interactions. This review aims to assess the impact of human-animal interactions on therapy dogs engaged in providing support to human health.

Bone Marrow Aspiration in Dogs: Indications and a Step-by-Step Tutorial
In dogs, bone marrow aspirates are often collected from the proximal humerus or ilium. A special 14- to 18-gauge needle with stylet is placed into the bone marrow cavity, and cells are subsequently aspirated. These needles are designed to penetrate cortical bone without becoming obstructed. Other sites in dogs include the sternum, ribs, and proximal femur. Aspiration from the pelvis and femur is challenging, if the region contains abundant adipose tissue.